Rivastigmine treatment resulted in significantly lower hepatic TG content and plasma ALT levels in the animals developing MASH, compared to vehicle-control mice, suggesting that drug treatment ameliorated MASH-associated steatosis and liver damage (Fig 4F and 4G). Here, GPT is linked to steatosis.